The Predictive Approaches to Treatment effect Heterogeneity (PATH) statement

Cited by (474)

Items 201–300 of 474

1. Association between the Edinburgh CT and genetic diagnostic criteria for cerebral amyloid angiopathy-associated lobar intracerebral haemorrhage and recurrent intracerebral haemorrhage: an individual patient data meta-analysis
   Mark Alexander Rodrigues, David Julian Seiffge, Neshika Samarasekera, Tom J. Moullaali, Joanna Marguerite Wardlaw, Stefanie Schreiber, Tyler P Behymer, Vivek J. Khandwala, Robert J. Stanton, Vaibhav S. Vagal et al. · 2025 · The Lancet Neurology
2. Estimating individualized treatment effects using a risk-modeling approach: an application to epidural steroid injections for lumbar spinal stenosis
   Pinyan Liu, Yitao Wu, Ziyu Xiao, Laura S. Gold, Patrick J. Heagerty, Thiru M. Annaswamy, Janna L. Friedly, Judith Axler Turner, Jeffrey G. Jarvik, Pradeep Suri · 2022 · Pain
3. Prespecification of subgroup analyses and examination of treatment-subgroup interactions in cancer individual participant data meta-analyses are suboptimal
   Ya Gao, Ming Liu, Shuzhen Shi, Mingming Niu, Li Jiang, Junhua Zhang, Fujian Song, Jinhui Tian · 2021 · Journal of Clinical Epidemiology
4. Neurosurgical Evidence and Randomized Trials: The Fragility Index
   Victor Volovici, Valerie I. Vogels, Rúben Dammers, Torstein Ragnar Meling · 2022 · World Neurosurgery
5. Clinical Trials in the 21st Century — Promising Avenues for Better Studies
   Michael J. Pencina, Bruce Thompson · 2022 · NEJM Evidence
6. Derivation and validation of a type 2 diabetes treatment selection algorithm for SGLT2-inhibitor and DPP4-inhibitor therapies based on glucose-lowering efficacy: cohort study using trial and routine clinical data
   John Dennis, Katherine Young, Andrew Peter McGovern, Bilal Akhter Mateen, Sebastian J. Vollmer, Michael D Simpson, William Henley, Rury R. Holman, Naveed A. Sattar, Ewan R. Pearson et al. · 2021 · medRxiv
7. Predicting individualized treatment effects of corticosteroids in community-acquired-pneumonia: a data-driven analysis of randomized controlled trials
   Jim M Smit, Philip A. van der Zee, Sara C. M. Stoof, Michel Egide van Genderen, Dominic Snijders, Wim G. Boersma, P. Confalonieri, Francesco Salton, Marco Confalonieri, M-C. Shih et al. · 2023 · medRxiv
8. Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank
   Daniel D. Shapiro, Edwin Jason Abel, Laurence K. Albiges, Dena J. Battle, Stephanie A Berg, Matthew T. Campbell, David F Cella, Katie Coleman, Benjamin Garmezy, Daniel M. Geynisman et al. · 2025 · Urologic Oncology Seminars and Original Investigations
9. Outcome risk model development for heterogeneity of treatment effect analyses: a comparison of non-parametric machine learning methods and semi-parametric statistical methods
   Edward Xu, Joseph C Vanghelof, Yiyang Wang, Anisha Patel, Jacob David Furst, Daniela Stan Raicu, Franz–Josef Neumann, Rory S Wolfe, Caroline X. Gao, John J. McNeil et al. · 2024 · BMC Medical Research Methodology
10. Unsupervised clustering approach to assess heterogeneity of treatment effects across patient phenotypes in randomized clinical trials
    Andrea Bellavia, Xinhui Ran, André Zimerman, Elliott Marshall Antman, Robert Patrick Giugliano, David A. Morrow, Sabina A. Murphy · 2024 · Contemporary Clinical Trials
11. Heterogeneous treatment effects of dexamethasone 12 mg versus 6 mg in patients with COVID ‐19 and severe hypoxaemia—Post hoc exploratory analyses of the COVID STEROID 2 trial
    Anders Granholm, Marie Warrer Munch, Nina Christine Andersen‐Ranberg, Sheila Nainan Myatra, Bharath Kumar Tirupakuzhi Vijayaraghavan, Balasubramanian Venkatesh, Vivekanand Jha, Rebecka Rubenson Wahlin, Stephan Matthias Jakob, Luca Cioccari et al. · 2022 · Acta Anaesthesiologica Scandinavica
12. A scoping review of statistical methods in studies of biomarker-related treatment heterogeneity for breast cancer
    Lukas Sollfrank, SC Linn, Michael Hauptmann, Katarzyna Jóźwiak · 2023 · BMC Medical Research Methodology
13. Heterogeneous Treatment Effects of Extracorporeal CO2 Removal in Acute Hypoxemic Respiratory Failure
    Ewan C. Goligher, James J. McNamee, José Dianti, Eddy Fan, Niall D. Ferguson, Arthur S. Slutsky, Daniel Francis McAuley · 2023 · American Journal of Respiratory and Critical Care Medicine
14. Evidence of subgroup differences in meta‐analyses evaluating medications for alcohol use disorder: An umbrella review
    Joshua David Wallach, Laura R. Glick, Ralitza V. Gueorguieva, Stephanie S. O’Malley · 2023 · Alcoholism Clinical and Experimental Research
15. Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT
    P.M. Burger, Deepak L. Bhatt, Jannick A N Dorresteijn, Stefan Koudstaal, Arend Mosterd, Fabrice M A C Martens, Philippe Gabríel Steg, Frank L.J. Visseren, for the REDUCE-IT Investigators, Joanne Ladner et al. · 2024 · European Heart Journal - Cardiovascular Pharmacotherapy
16. Identifying target populations to align with decision-makers’ needs
    Jennifer Leigh Lund, Anthony Matthews · 2024 · American Journal of Epidemiology
17. An approach to explore for a sweet spot in randomized trials
    Donald A. Redelmeier, Robert John Tibshirani · 2019 · Journal of Clinical Epidemiology
18. Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial
    Samuel W. Reinhardt, Nihar R. Desai, Yuanyuan Tang, Philip G. Jones, Jeremy Ader, John A. Spertus · 2021 · PLoS ONE
19. Combining randomized and non‐randomized data to predict heterogeneous effects of competing treatments
    Konstantina Chalkou, Tasnim Hamza, Pascal Benkert, Jens Kühle, Chiara Zecca, Gabrielle Simoneau, Fabio Pellegrini, Andrea Manca, Matthias Egger, Georgia Salanti · 2024 · Research Synthesis Methods
20. Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors
    Katherine Young, Eram Haider McInnes, Robert J. Massey, Anna R Kahkohska, Scott J. Pilla, Sridharan Raghavan, Maggie A. Stanislawski, Deirdre Kay Tobias, Andrew Peter McGovern, Adem Y. Dawed et al. · 2023 · medRxiv
21. Sub-phenotyping in critical care: a valuable strategy or methodologically fragile path?
    Jim M Smit, Annemijn H. Jonkman, Jesse H. Krijthe · 2025 · Intensive Care Medicine Experimental
22. Statistical approaches in ambispective cohort studies: Challenges and methodological insights
    Pattabhi Ramayya Machiraju, Gomathi Priya Jeyapal · 2025 · Perspectives in Clinical Research
23. Estimating the Individualized Effect of Tooth Extraction before Radiotherapy on Osteoradionecrosis Using Causal Machine Learning
    Mohammad Moharrami, Erin E. Watson, S. Singhal, S.H. Huang, Christopher M. K. L. Yao, A. Hosni, Carlos Quiñonez, Michael Glogauer · 2026 · Journal of Dental Research
24. Use of conditional estimates of effect in cancer epidemiology: An application to lung cancer treatment
    Jazeel Abdulmajeed, Malkan Khatib, Mohamad Wajeh Dulli, Stephanie Sioufi, Azhar Al-Khulaifi, Jennifer Stone, Luis Furuya‐Kanamori, Adedayo A. Onitilo, Suhail A.R. Doi · 2023 · Cancer Epidemiology
25. WATCH : A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors
    Konstantinos Sechidis, Sophie B. Sun, Yao Chen, Jiarui Lu, Cong Zhang, Mark Baillie, David I. Ohlssen, Marc Vandemeulebroecke, Rob Hemmings, Stephen J. Ruberg et al. · 2024 · Pharmaceutical Statistics
26. Aspirin and healthy lifespan in older people: main outcome of the ASPREE-XT observational study
    Raj C. Shah, Joanne L. Ryan, Katherine L. Webb, Rory S Wolfe, Andrew Tan Chan, Trevor T.‐J. Chong, Michael E. Ernst, Sara E Espinoza, Olivia Flynn, Song Yuin Lee et al. · 2025 · The Lancet Healthy Longevity
27. Many Paths to Recovery: The Case for Treatment Pluralism
    Jared K. Powell, Amy W. McDevitt, Chad Cook · 2026 · Journal of Orthopaedic and Sports Physical Therapy
28. Competing Benefits and Competing Hazards: The Benefit to Harm Balance in Individual Patients in Rational Therapeutics
    Robin Esmond Ferner, Jeffrey K Aronson · 2024 · Drug Safety
29. Machine Learning to Predict Individualized Treatment Effects of Sodium Bicarbonate for Patients With Out-of-Hospital Cardiac Arrest
    Chi‐Hsin Chen, Cheng‐Yi Fan, Yi‐Chien Kuo, Chih‐Hung Wang, Hung‐Wen Chiu, Edward Pei‐Chuan Huang · 2025 · Critical Care Medicine
30. Testing for a Sweet Spot in Randomized Trials
    Donald A. Redelmeier, Deva Thiruchelvam, Robert John Tibshirani · 2021 · Medical Decision Making
31. Estimating Patient-Specific Relative Benefit of Adding Biologics to Conventional Rheumatoid Arthritis Treatment
    Yan Luo, Konstantina Chalkou, Satoshi Funada, Georgia Salanti, Toshi A. Furukawa · 2023 · JAMA Network Open
32. Drug Prescription Based on Predicted Treatment Responsiveness: An Application to the PROSPER Randomised Controlled Trial
    Tri‐Long Nguyen, Stella Trompet, John Brodersen, Jeroen Hoogland, Thomas P. A. Debray, Naveed A. Sattar, J. Wouter Jukema, Rudi G. J. Westendorp · 2022 · European Journal of Preventive Cardiology
33. Risk–benefit trade-offs and precision utilities in phase I-II clinical trials
    Pavlos Msaouel, Juhee Lee, Peter F. Thall · 2023 · Clinical Trials
34. Re-Analyses of 8 Historical Trials in Cardiovascular Medicine Assessing Multimorbidity Burden and Its Association with Treatment Response
    Andrew Foy, Élise Schaefer, Mohammed Ruzieh, Matthew S. Nudy, Omaima Mohamed Ali, Vernon M. Chinchilli, Gerald V. Naccarelli · 2024 · The American Journal of Medicine
35. Computational simulation of the potential improvement in clinical outcomes of cardiovascular diseases with the use of a personalized predictive medicine approach
    Xander Jacquemyn, Jef Van den Eynde, Bhargava Kumar Chinni, David M Danford, Shelby Kutty, Cedric Manlhiot · 2024 · Journal of the American Medical Informatics Association
36. Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma
    Carolien C. H. M. Maas, David V. Klaveren, Müjde Durmaz, Otto J. Visser, Djamila E. Issa, Eduardus F. M. Posthuma, Josée M. Zijlstra, Martine E.D. Chamuleau, Pieternella Johanna Lugtenburg, Marie José Kersten et al. · 2024 · Blood Cancer Journal
37. Identifying adults with acute rhinosinusitis in primary care that benefit most from antibiotics: protocol of an individual patient data meta-analysis using multivariable risk prediction modelling
    Roderick P Venekamp, Jeroen Hoogland, Maarten van Smeden, Maroeska Mariet Rovers, An IM De Sutter, Daniel J. Merenstein, Gerrit Adrianus van Essen, Laurent Kaiser, Helena Liira, Paul S Little et al. · 2021 · BMJ Open
38. Comparison of causal forest and regression-based approaches to evaluate treatment effect heterogeneity: An application for type 2 diabetes precision medicine
    Ashwini Venkatasubramaniam, Bilal Akhter Mateen, Beverley M. Shields, Andrew Tym Hattersley, Angus G. Jones, Sebastian J. Vollmer, John Dennis · 2022 · medRxiv
39. Your Mileage May Vary
    Derek C. Angus · 2024 · JAMA
40. Potential clinical impact of predictive modeling of heterogeneous treatment effects: scoping review of the impact of the PATH Statement
    Joe V. Selby, Carolien C. H. M. Maas, BRUCE H. FIREMAN, David M. Kent · 2024 · medRxiv
41. Guideline Updates Needed: Closure Devices to Prevent Recurrent Stroke in Patients With Patent Foramen Ovale
    Jeffrey L. Saver · 2024 · Journal of the American Heart Association
42. Refining the use of neuromuscular blockade in ARDS: lessons from a post hoc Markov model re-analysis of the ACURASYS trial
    Inès Lakbar, Audrey DE JONG, Denise Battaglini · 2025 · Intensive Care Medicine
43. Addressing heterogeneous treatment effects in acute care syndromes: principles and practical considerations
    Fernando Godinho Zampieri, Sean M. Bagshaw, Alexandre Biasi Cavalcanti · 2025 · Thorax
44. Heterogeneity of Cardiovascular Effects of Second‐Line Glucose‐Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk
    Yihong Deng, Eric C. Polley, Jeph S. Herrin, KAVYA SINDHU SWARNA, David M. Kent, Joseph S. Ross, Bradley A. Maron, Mindy M. Mickelson, Rozalina G. McCoy · 2025 · Journal of the American Heart Association
45. Intravenous thrombolysis for acute central retinal artery occlusion: Protocol for a systematic review and individual participant data meta-analysis of randomized controlled trials
    Brian Mac Grory, Cécile Preterre, Pierre Lebranchu, Stephen James Ryan, Øystein Kalsnes Jørstad, Morten Carstens Moe, Johannes Tünnerhoff, Martin S. Spitzer, Carsten Grohmann, Oana M. Dumitrascu et al. · 2026 · PLoS ONE
46. Estimating and discovering heterogeneous treatment effects using machine learning in epidemiological studies: a practical guide
    Toshiaki Komura, Falco J. Bargagli-Stoffi, Onyebuchi A. Arah, Kosuke Inoue · 2026 · International Journal of Epidemiology
47. Study protocol for a randomised controlled trial evaluating the clinical effect of antibiotic prophylaxis in children with recurrent respiratory tract infections: the Approach study
    Daphne Peeters, Nan van Geloven, Loes E. Visser, Debby Bogaert, Annemarie M. C. van Rossum, Gertjan J. A. Driessen, Lilly M. Verhagen · 2021 · BMJ Open
48. Design and analysis considerations for investigating patient subgroups of interest within cancer clinical trials
    Gina L. Mazza, Eva Culakova, Danielle M. Enserro, James J. Dignam, Joseph M. Unger · 2025 · JNCI Monographs
49. Limitations in the Design of Critical Care Studies and Suggestions for Future Research Directions
    G. Umberto Meduri, Simone Lanini, Jim M Smit · 2026 · Seminars in Respiratory and Critical Care Medicine
50. Endovascular versus neurosurgical aneurysm treatment: study protocol for the development and validation of a clinical prediction tool for individualised decision making
    Jordi de Winkel, Bob Roozenbeek, Simone A. Dijkland, Rúben Dammers, Pieter‐Jan van Doormaal, Mathieu van der Jagt, David V. Klaveren, Diederik W.J. Dippel, Hester Floor Lingsma · 2022 · BMJ Open
51. Methodological concerns about “concordance-statistic for benefit” as a measure of discrimination in predicting treatment benefit
    Yuan Xia, Paul Gustafson, Mohsen Sadatsafavi · 2023 · Diagnostic and Prognostic Research
52. Assessing the properties of patient-specific treatment effect estimates from causal forest algorithms under essential heterogeneity
    John M. Brooks, Cole G. Chapman, Brian Chen, Sarah Bauer Floyd, Neşet Hikmet · 2024 · BMC Medical Research Methodology
53. Group-by-Treatment Interaction Effects in Comparative Bioavailability Studies
    Helmut Schütz, Divan Aristo Burger, Erik Cobo, David N. Dubins, Tibor Farkás, Detlew Labes, Benjamin J. Lang, Jordi Ocaña, Arne Ring, Anastasia Shitova et al. · 2024 · The AAPS Journal
54. Differential effect by chronic disease risk: A secondary analysis of the ChooseWell 365 randomized controlled trial
    Jessica Szu-Chi Cheng, Douglas E. Levy, Jessica L. McCurley, Eric B. Rimm, Emily D. Gelsomin, Anne N. Thorndike · 2024 · Preventive Medicine Reports
55. Exploring heterogeneity of treatment effect in patients with sepsis: Protocol for a scoping review
    Lise Søndergaard, Anne Sofie Andreasen, Anders Perner, Carsten Utoft Niemann · 2024 · Acta Anaesthesiologica Scandinavica
56. Prediction Models for Mortality in Patients With Moderate to Severe ARDS Treated in the ICU
    Katrijn Daenen, Sara C. M. Stoof, Hugo D.G. van Willigen, Anders C. Boyd, Virgil A. S. H. Dalm, Diederik A M P J Gommers, Eric C. M. Van Gorp, Abraham J. Valkenburg, Henrik Endeman, Jilske Antonia Huijben · 2025 · CHEST Critical Care
57. Lost in Translation Between Evidence and Recommendations: Expert Opinion is Needed to Define “Level I”
    Victor Volovici, Ewout Willem Steyerberg · 2021 · World Neurosurgery
58. Subgroup Analysis in Pulmonary Hypertension-Specific Therapy Clinical Trials: A Systematic Review
    Héctor Rodríguez Ramallo, Nerea Báez Gutiérrez, Remedios Otero, S Flores-Moreno, L Abdel-kader Martín · 2022 · Journal of Personalized Medicine
59. Another Nudge to Overcome the Treatment-Risk Paradox in Blood Pressure Management
    Joseph A. Diamond, Adam E. Schussheim, Robert A. Phillips · 2021 · Journal of the American College of Cardiology
60. Covariate Selection for Estimating Individual Treatment Effects in Psychotherapy Research: A Simulation Study and Empirical Example
    Robin Anno Wester, Julian A. Rubel, Axel Mayer · 2021
61. Awaiting the verdict: Statins and the road ahead for primary prevention in older adults
    Márlon Juliano Romero Aliberti, Caio A.M. Tavares, Nicholas M. Pajewski · 2024 · Journal of the American Geriatrics Society
62. Designing Future Cardiac Arrest Trials to Accommodate Heterogeneous Treatment Effects
    Gabriele Lileikyte, Lucas L. Marinho, Peter J. McGuigan, Edy Yong Kim, Michael Oscar Harhay, Fernando Godinho Zampieri, Alexandra B. Spicer, Matthew M. Churpek, Niklas Nielsen, Patrick R. Lawler · 2026 · JACC Advances
63. Beyond Conventional Meta-Analysis: A Meta-Learning Model to Predict Cohort-Level Mortality After Transcatheter Aortic Valve Replacement (TAVR)
    Yamil Liscano, Darly Martínez Guevara, Gustavo Andrés Urriago-Osorio, John Quintana · 2025 · Journal of Cardiovascular Development and Disease
64. Sex differences in trial representation and the cardiovascular effectiveness of newer glucose‐lowering agents in patients with and without type 2 diabetes: A systematic review and meta‐analysis of cardiovascular outcome trials
    Magdaline Zawadka, Erwin Taguiam, Mê‐Linh Lê, Rohan Sanjanwala, Shuangbo Liu, Ashish H. Shah, Setor Kwadzo Kunutsor · 2026 · Diabetes Obesity and Metabolism
65. A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy
    Mark Canney, Sana Shan, Lee Er, Laurent Billot, Jialin Han, Muh Geot Wong, Helen Monaghan, Michelle Hladunewich, Lai Seong Hooi, Vivekanand Jha et al. · 2026 · Kidney International
66. Common reporting errors in subgroup analysis: a comparison of interaction and stratified regression models
    Chingkwong Tsoi, Ran Sun · 2026 · BMC Medical Research Methodology
67. Effectiveness and clinical relevance of kinesio taping in musculoskeletal disorders: an overview of systematic reviews and evidence mapping
    Qingcong Mo, Zhe Deng, Jialing Zheng, Tong Wu, Fangfei Hu, Siqi Xu, Jihua Zou, Xiaoyan Zheng · 2026 · BMJ Evidence-Based Medicine
68. Late thrombectomy for ischaemic stroke
    Diederik W.J. Dippel, Bob Roozenbeek · 2021 · The Lancet
69. El Cálculo del Tamaño Muestral en Ciencias de la Salud: Recomendaciones y Guía Práctica
    Rubén Fernández-Matías · 2023 · Journal of MOVE and Therapeutic Science
70. Survival after resection of malignant peripheral nerve sheath tumors: Introducing and validating a novel type-specific prognostic model
    Ibtissam Acem, Ewout Willem Steyerberg, Marta Spreafico, Dirk Jan Grünhagen, Dario Callegaro, Robert J. Spinner, Courtney A. Pendleton, Jan Henk Coert, Rosalba Miceli, Giulia Abruzzese et al. · 2024 · Neuro-Oncology Advances
71. A randomised controlled trial comparing epinephrine and dexamethasone to placebo in the treatment of infants with bronchiolitis: the Bronchiolitis in Infants Placebo versus Epinephrine and Dexamethasone (BIPED) study protocol
    Amy Catherine Plint, Anna Heath, Tremaine Rowe, Kristina I. Vogel, Natasha Wills-Ibarra, Sharon O’Brien, Meredith Louise Borland, David Wyatt Johnson, Joseph J. Zorc, Petros Pechlivanoglou et al. · 2025 · ERJ Open Research
72. Prognosis and prediction of antibiotic benefit in adults with clinically diagnosed acute rhinosinusitis: an individual participant data meta-analysis
    Jeroen Hoogland, Toshihiko Takada, Maarten van Smeden, Maroeska Mariet Rovers, An IM De Sutter, Daniel J. Merenstein, Laurent Kaiser, Helena Liira, Paul S Little, Heiner C. Bucher et al. · 2023 · Diagnostic and Prognostic Research
73. Risk subgroups and intervention effects among infants at high risk for peanut allergy: A model for clinical decision making
    Yuxiang Li, Ashley Lynn Devonshire, Bin Huang, Sandra Andorf · 2024 · Clinical & Experimental Allergy
74. Advancing Personalized Medicine Through Prediction
    A. Russell Localio, Cynthia D. Mulrow, Michael E Griswold · 2019 · Annals of Internal Medicine
75. Authors’ Reply: Kidney Histopathology in ANCA-Associated Vasculitides Treated with Plasma Exchange
    Dorian Nezam, Raphaël Porcher, François Grolleau, Benjamin Terrier · 2022 · Journal of the American Society of Nephrology
76. Individual Differences in the Effects of Neighborhood Socioeconomic Deprivation on Intertemporal Decision-Making and Psychotic-Like Experiences in Children
    Jiook Cha, Junghoon Park, Minje Cho, Eunji Lee, Bo‐Gyeom Kim, Gakyung Kim, Yoonjung Yoonie Joo · 2024 · Research Square
77. Making (numerical) sense of recent trials comparing balanced and normal saline intravenous solutions in the critically ill
    Fernando Godinho Zampieri, Sean M. Bagshaw · 2023 · British Journal of Anaesthesia
78. Lifting the veil off treatment effect heterogeneity
    Herbert I. Weisberg, Megan D. Higgs · 2024 · American Heart Journal
79. Individual participant data meta‐analysis to examine linear or non‐linear treatment‐covariate interactions at multiple time‐points for a continuous outcome
    Miriam Hattle, Joie Ensor, Katie Scandrett, Marienke van Middelkoop, Daniëlle van der Windt, Melanie Ann Holden, Richard D Riley · 2024 · Research Synthesis Methods
80. Systematic evaluation of subgroup analyses of inhaled treprostinil in pulmonary hypertension due to interstitial lung disease
    Pablo Martínez-Puig, Nerea Báez Gutiérrez, Héctor Rodríguez Ramallo, Laila Abdel‐Kader Martín, Remedios Otero · 2025 · PLoS ONE
81. Adaptations and Heterogeneity of Treatment Effects in Platform Trials—Protocol for Two Methodological Studies
    Tine Sylvest Meyhoff, Aksel Karl Georg Jensen, Anders Perner, Ewan C. Goligher, Marion Campbell, Morten Hylander Møller, Anders Granholm · 2025 · Acta Anaesthesiologica Scandinavica
82. Precision medicine evaluation of heterogeneity of treatment effect for a time-to-event outcome with application in a trial of Initial treatment for people living with HIV
    Yu Zheng, Judy Currier, Michael D. Hughes · 2025 · Clinical Trials
83. Observational vs. Experimental Data When Making Automated Decisions Using Machine Learning
    Carlos Fernández-Loría, Foster John Provost · 2025 · INFORMS Journal on Data Science
84. Direct Effect Modeling Methods to Estimate Heterogeneity of Treatment Effects
    Andrea J. Cook, Patrick J. Heagerty · 2025 · JAMA Network Open
85. Assessing Benefit in Patients With Heart Failure and Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk Stratification
    Christopher M. O’Connor, Sarah Rathwell, Devan V. Mehrotra, Stefano Corda, Ciaran J. McMullan, Carolyn S.P. Lam, Justin Adrian Ezekowitz, Burkert Piekse, Adrian F. Hernandez, Kevin Joseph Anstrom et al. · 2025 · Journal of Cardiac Failure
86. PCISOS Risk Profiles Stratify Heterogeneous Outcomes in Minor Posterior Circulation Ischemic Stroke: A Post Hoc Analysis of the CHANCE-2 Trial
    Xiaoyu Lin, Cang Guo, Xia Meng, Xingquan Zhao, Hao Li, Yongjun Wang, Jialei Yang · 2025 · Stroke
87. What Do Policies Value?
    Daniel Björkegren, Joshua Evan Blumenstock, Samsun Knight · 2025 · The Review of Economic Studies
88. Individualised treatment effect prediction: the benefit of initial biological treatment in early rheumatoid arthritis
    Sina Fadaei, Julia Spierings, Jacob M. van Laar, J. W. J. Bijlsma, Johannes W. G. Jacobs, Paco M J Welsing · 2025 · EULAR Rheumatology Open
89. A randomised controlled trial comparing epinephrine and dexamethasone to placebo in the treatment of infants with bronchiolitis (BIPED study): a statistical analysis plan
    Anna Heath, David Rios, Kristina I. Vogel, Tremaine Rowe, Natasha Wills-Ibarra, Ed A Oakley, Martin Offringa, Petros Pechlivanoglou, Terry Paul Klassen, Stuart R. Dalziel et al. · 2025 · Trials
90. Target trial emulation in hypertension research: a scoping review of current applications and methodological practices
    Amir Habibdoust, Hanxiao Zuo, Richelle J. Koopman, Aditi Gupta, Diego R. Mazzotti, Xing Song · 2025 · Journal of Hypertension
91. Universal vs selective tranexamic acid use for preventing blood loss after cesarean delivery: a reanalysis of the TRAAP-2 trial
    Thomas Ferté, Antoine Bénard, Kilian Trin, Hugo Madar, Catherine Deneux‐Tharaux, Loı̈c Sentilhes · 2026 · American Journal of Obstetrics and Gynecology
92. Physical Activity Recommendations Tailored by a Predictive Model for Adults With High Blood Pressure: Observational Study
    Yuhui Yang, Manqing Chen, Weiwei Hu, Yifan Fu, Xingyan Li, Zhenli Liao, Hongman Feng, Yaling Zhao, Leilei Pei, Baibing Mi et al. · 2026 · Journal of Medical Internet Research
93. Heterogeneity in Treatment Effects of Reduced Versus Standard Dose of Cabazitaxel in Metastatic Castration‐Resistant Prostate Cancer
    Wataru Fukuokaya, Keiichiro Mori, Takafumi Yanagisawa, Kagenori Ito, Fumihiko Urabe, Paweł Rajwa, Shahrokh François Shariat, Takahiro Kimura, Akihiro Hirakawa · 2026 · Cancer Medicine
94. How to determine the optimal duration of anticoagulation for VTE: an evidence-based decision-analytical approach
    Benjamin Djulbegović, Charles S. Greenberg · 2026 · Blood Advances
95. Statistical analysis plan for the Strategy to Avoid Excessive Oxygen using Autonomous Oxygen Titration Intervention (SAVE-O2 AI) trial: protocol
    David J. Douin, John D. Rice, Mengli Xiao, Laurel E. Beaty, Claire J. Guo, Cori Withers, Amy Sullivan, Erin L. Anderson, Alex Cheng, Mary K. Banasiewicz et al. · 2026 · BMJ Open
96. Multidimensional Recovery Trajectories Following Physiotherapy with or Without Pain Education in People with Chronic Low Back Pain
    Ahmed Alalawi · 2026 · Journal of Clinical Medicine
97. Building and validating machine learning models to predict appendiceal perforation during conservative treatment of fecalith-associated appendicitis: a 20-algorithm multicenter retrospective analysis
    Youlong Zhu, Jiawei FENG, R. Liu, Wang Ren, Xiao Ma, Ning Wang, Longbo Gong, Feifei Kong · 2026 · Scientific Reports
98. Machine learning optimization of obstructive sleep apnea screening: development and validation of a gradient boosting prediction model with a clinical implementation framework
    Tengteng Liu, 却岚, Weiwei Bai, Hong Yao · 2026 · Frontiers in Medicine
99. Using causal machine learning and real world data to improve dose response decision making for secukinumab in psoriatic arthritis
    Uta Kiltz, Thomas Glassen, Jan Brandt-Juergens, Ferenc Kiss, Daniel Peterlik, Benjamin Gmeiner · 2026 · Scientific Reports
100. The heterogeneous treatment effect of adjuvant therapy with corticosteroids in patients with Community-Acquired Pneumonia: a review
     Jim M Smit, A. Torres, Philip A. van der Zee, Jesse H. Krijthe, Ignacio Martín‐Loeches · 2026 · Pneumonia